Loading organizations...
LYNK Pharmaceuticals is a technology company.
LYNK Pharmaceuticals is a clinical-stage biotechnology company developing innovative small molecule drugs. Its focus areas are oncology, immunology, and inflammatory diseases. The pipeline includes the highly selective JAK1 inhibitor, Zemprocitinib, with positive Phase III results for inflammatory conditions. This demonstrates their targeted approach to complex disease pathways.
Founded in 2018, LYNK Pharmaceuticals was established by veteran drug hunters from prominent pharmaceutical companies. Key founders include CEO Dr. Zhao-Kui (ZK) Wan, Chief Science Officer Dr. Jun Wang, and COO Chen Ji. Their insight: leveraging decades of pharmaceutical R&D experience to drive novel drug discoveries for unmet medical needs.
LYNK Pharmaceuticals develops therapies for patients with cancers, autoimmune disorders, and chronic inflammatory diseases. The company is committed to advancing its innovative small molecule pipeline, addressing significant unmet clinical demand. Its vision is to be a leader in discovering and delivering next-generation medicines that improve global patient outcomes.
LYNK Pharmaceuticals has raised $122.2M across 3 funding rounds.
LYNK Pharmaceuticals has raised $122.2M in total across 3 funding rounds.
LYNK Pharmaceuticals has raised $122.2M in total across 3 funding rounds.
LYNK Pharmaceuticals's investors include China Grand Prosperity Investment, Lilly Asia Ventures, New Alliance Capital, Liando Investment, HEDA Ventures, Legend Capital, Med-Fine Capital.
LYNK Pharmaceuticals is a clinical-stage biotech company dedicated to discovering and developing novel small-molecule medicines targeting oncology, immunology, and inflammatory diseases, with a primary focus on autoimmune indications.[1][2][3] It serves patients with unmet needs in areas like rheumatoid arthritis, atopic dermatitis, multiple sclerosis, and psoriasis through differentiated assets such as JAK1 inhibitors (Phase 3), tissue-restricted JAK inhibitors (Phase 2), and CNS-penetrant TYK2 inhibitors (IND stage).[2][5][6] The company solves challenges in immune-mediated diseases by advancing selective inhibitors and degraders that offer best-in-class profiles for efficacy and tissue specificity, demonstrating growth through recent FDA IND clearance for LNK01006 and a major licensing deal with Formation Bio.[2][5]
LYNK Pharmaceuticals emerged as a biotech focused on therapeutic R&D in immunology and oncology, though specific founding year and founders are not detailed in available sources.[1][3] Key leadership includes CEO Zhao-Kui (ZK) Wan, who has guided pivotal advancements like the partnership with Formation Bio for global rights (ex-Greater China) to LNK01006, a CNS-penetrant TYK2 inhibitor.[5] Early traction includes advancing multiple assets into clinical stages, such as LNK01001 (JAK1 inhibitor) into Phase 3 for inflammatory and immunology indications, and securing FDA IND clearance for LNK01006 to enable first-in-human trials.[2][5][6]
LYNK rides the wave of precision immunology therapies, capitalizing on validated JAK/TYK2 mechanisms applied to high-unmet-need areas like CNS immune modulation and tissue-specific inflammation amid rising autoimmune disease prevalence.[5][6] Timing aligns with FDA efficiencies (e.g., rapid IND for LNK01006) and AI-driven drug development trends, as seen in Formation Bio's "Known In New" strategy repurposing de-risked assets.[5] Market forces favoring it include booming demand for oral small-molecule alternatives to biologics, with Lynk influencing the ecosystem through licensing deals that expand global reach and fund parallel pipelines in Greater China.[2][5]
LYNK's momentum positions it for Phase 3 readouts on LNK01001 and Phase 2 data from LNK01004, alongside clinic entry for LNK01006 via Formation Bio.[2][5][6] Trends like AI-optimized trials and CNS-penetrant immunotherapies will shape its path, potentially evolving Lynk into a multi-asset player with broader oncology/immunology impact through degraders and new INDs. As clinical-stage biotech advances yield partnerships, Lynk exemplifies how targeted inhibitors address immunology gaps, building on its core mission of novel medicines for unmet needs.[1][5]
LYNK Pharmaceuticals has raised $122.2M across 3 funding rounds. Most recently, it raised $44.1M Series C in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 21, 2023 | $44.1M Series C | China Grand Prosperity Investment | Lilly Asia Ventures, New Alliance Capital |
| Jun 1, 2023 | $28.1M Series C | China Grand Prosperity Investment, Liando Investment | |
| Aug 29, 2021 | $50.0M Series B | Lilly Asia Ventures | HEDA Ventures, Legend Capital, Med-Fine Capital, New Alliance Capital |